Trial reportPharmacology, biochemistry, and behavior2019
The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study.
Trial report in Pharmacology, biochemistry, and behavior, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Lorcaserin Effects on Cocaine Craving and Drug-Reinforced Behavior
Treatment With Lorcaserin for Cocaine Use: The TLC Study
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder.Drug and alcohol dependence · 2024Trial
- The 5-HTPharmacology research & perspectives · 2021Trial
- Trial
- Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder.Drug and alcohol dependence · 2020Trial
- Lorcaserin modulation of semantic drug cue-elicited effective brain connectivity in persons with cocaine and opioid use disorders.Psychiatry research. Neuroimaging · 2025Article
- Neural circuits controlling choice behavior in opioid addiction.Neuropharmacology · 2023Review
- Evaluation of the 5-HTPharmacological reports : PR · 2023Article
- The antidepressant agomelatine attenuates morphine-induced reinstatement but not self-administration or precipitated withdrawal.Pharmacology, biochemistry, and behavior · 2023Article
- Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review.Brain sciences · 2022Review
- Logical fallacies and misinterpretations that hinder progress in translational addiction neuroscience.Journal of the experimental analysis of behavior · 2022Article
- Clinical neuropharmacology of cocaine reinforcement: A narrative review of human laboratory self-administration studies.Journal of the experimental analysis of behavior · 2022Review
- Heightened cocaine-seeking in male rats associates with a distinct transcriptomic profile in the medial prefrontal cortex.Frontiers in pharmacology · 2022Article
- Decline and Pronounced Regional Disparities in Medical Cocaine Usage in the United States.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2021Article
- Confronting the challenge of failed translation in medications development for substance use disorders.Pharmacology, biochemistry, and behavior · 2021Article
- Effects of buprenorphine/lorcaserin mixtures on preference for heroin, cocaine, or saline over food using a concurrent choice procedure in rhesus monkeys.Drug and alcohol dependence · 2021Article
- Converging vulnerability factors for compulsive food and drug use.Neuropharmacology · 2021Review
- 5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers.Addiction biology · 2021Article
- Improving Translational Research Outcomes for Opioid Use Disorder Treatments.Current addiction reports · 2021Article
- Medications Development for Treatment of Opioid Use Disorder.Cold Spring Harbor perspectives in medicine · 2021Review
- Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial.Frontiers in psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundLorcaserin is a modestly selective agonist for 2C serotonin receptors (5-HT METHODS AND
participantsWe evaluated effects of single 10 mg doses of lorcaserin on the subjective and reinforcing effects of cocaine, using a randomized, double-blind, within-subject, cross-over design. Male, non-treatment-seeking, regular cocaine users received either single doses of oral placebo (n = 9) or lorcaserin (n = 9), followed by low- or high- doses of intravenous cocaine (0.23 or 0.46 mg/kg-injection). They were then allowed to self-administer the lower dose of cocaine.
resultsCocaine was well tolerated after lorcaserin pretreatment. Oral lorcaserin did not modify the number of cocaine injections self-administered. However, it prolonged the time over which participants made intravenous choices relative to the duration of monetary (cash) decisions. Lorcaserin increased ratings of 'high' and 'stimulated' after low-dose cocaine or vehicle, but decreased craving for cocaine after intravenous vehicle. It also caused small but significant increases in heart rate following noncontingent injections of intravenous placebo or cocaine. When active cocaine was self-administered, lorcaserin decreased heart rate after selection of a monetary choice, but increased it following an intravenous choice.
conclusionsCombined treatment with cocaine and lorcaserin was safe in a limited number of subjects, but did not diminish cocaine-motivated behavior or drug-induced 'high'. Some positive subjective effects of cocaine were enhanced by lorcaserin, and it delayed intravenous choices and decreased craving under some conditions. Effects on heart rate depended on the type of reinforcer being self-administered.
trial registrationclinicaltrials.gov Identifier, NCT02680288.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.